Hyperplasia News and Research RSS Feed - Hyperplasia News and Research

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research. [More]
Experts discuss recent controversies related to breast cancer screening recommendations

Experts discuss recent controversies related to breast cancer screening recommendations

In 2015, American Cancer Society caused a stir in the oncology community—and among women in general—with the updated recommendation that women of average risk for breast cancer should commence annual mammography at age 45. [More]
Prostatic artery embolization improves sleep, quality of life for men with enlarged prostates

Prostatic artery embolization improves sleep, quality of life for men with enlarged prostates

An innovative interventional radiology treatment for men with enlarged prostates decreases the number of times they wake to urinate in the night, according to research presented at the Society of Interventional Radiology's 2016 Annual Scientific Meeting. Researchers said the majority of men with enlarged prostates and lower urinary tract symptoms reported better sleep that resulted in an improved quality of life after they underwent a treatment called prostatic artery embolization (PAE). [More]
MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx. [More]
New imaging test detects prostate cancer much better than any other tests in use today

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today. [More]
Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome. [More]
UVA opens clinical trial to examine non-surgical treatment for lower urinary tract symptoms

UVA opens clinical trial to examine non-surgical treatment for lower urinary tract symptoms

University of Virginia Health System researchers have opened a national clinical trial examining a non-surgical treatment for lower urinary tract symptoms caused by an enlarged prostate. [More]
Undetected cancer among women undergoing gynecologic surgery more common than previously thought

Undetected cancer among women undergoing gynecologic surgery more common than previously thought

Minimally invasive gynecologic surgeries have advantages for patients, including shorter hospital stays, quicker recoveries, and less pain. However, power morcellation, a technique which cuts the uterus or fibroid into small pieces in order to extract them from the abdomen through a small incision, may worsen a woman's prognosis if a cancer is morcellated unintentionally. [More]
Review of haemodynamics in stent development shows spiral flow may be key to improving peripheral arterial stent performance

Review of haemodynamics in stent development shows spiral flow may be key to improving peripheral arterial stent performance

Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces that 'Haemodynamics and Flow Modification Stents for Peripheral Arterial Disease: A Review’, co-authored by VFT’s non-executive Medical Director Graeme Houston, has been published in the Annals of Biomedical Engineering. The paper reviews the importance of haemodynamics in stent development as a method of improving patency and longevity of the stent. [More]
SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

The US Food and Drug Administration has approved SonaCare Medical's Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables treatment of organ-confined prostate disease while preserving surrounding healthy tissue, without radiation or surgery. [More]
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual. [More]
Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Working with tissue, blood and DNA from six people with precancerous and cancerous lung lesions, a team of Johns Hopkins scientists has identified what it believes are among the very earliest “premalignant” genetic changes that mark the potential onset of the most common and deadliest form of disease. [More]
Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis. [More]
Researchers refine breast cancer risk model to give more accurate assessment

Researchers refine breast cancer risk model to give more accurate assessment

A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than one million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher. [More]
The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition. [More]
Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures. [More]
Study reveals new information about role of abdominal fat in teens with CAH

Study reveals new information about role of abdominal fat in teens with CAH

Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD). [More]
Non-invasive prenatal testing for Down's syndrome acceptable to parents

Non-invasive prenatal testing for Down's syndrome acceptable to parents

Non-invasive prenatal testing (NIPT) for Down's syndrome is feasible, acceptable to parents, and could be introduced into the National Health Service, UK researchers say. The results of a National Institute for Health Research study carried out by the first NHS laboratory to provide NIPT testing will be reported to the annual conference of the European Society of Human Genetics today (Saturday). [More]
Study highlights link between poor sleep quality and impact of severe LUTS in some men

Study highlights link between poor sleep quality and impact of severe LUTS in some men

Sleep quality may have an impact on the severity of lower urinary tract symptoms, or LUTS, in some men, according to new research presented during the 110th Annual Scientific Meeting of the American Urological Association. [More]
Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014. [More]
Advertisement
Advertisement